News
At last week’s American Chemical Society Spring meeting, Bristol Myers Squibb Co. discussed the development of a potent, orally bioavailable and highly selective cereblon (CRBN)-mediated ...
The company will also highlight preclinical study of ARV-393, an investigational PROTAC BCL6 degrader, in combination with standard of care therapies. The poster highlights the potential for ARV-393 ...
Company to highlight preclinical study of ARV-393, an investigational PROTAC BCL6 degrader, in combination with standard of care therapies NEW HAVEN, Conn., April 21, 2025 (GLOBE NEWSWIRE) -- Arvinas, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results